Sorrento Therapeutics Inc Stock Other OTC
Equities
US83587F1030
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
04-10 | Sorrento Therapeutics, Inc. Emerged from Bankruptcy | CI |
03-15 | Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs | MT |
Sales 2021 | 52.9M 72.1M | Sales 2022 | 62.84M 85.64M | Capitalization | 411M 561M |
---|---|---|---|---|---|
Net income 2021 | -428M -583M | Net income 2022 | -573M -781M | EV / Sales 2021 | 29.1 x |
Net Debt 2021 | 111M 151M | Net Debt 2022 | 84.53M 115M | EV / Sales 2022 | 7.89 x |
P/E ratio 2021 |
-3.2
x | P/E ratio 2022 |
-0.65
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 97.77% |
Managers | Title | Age | Since |
---|---|---|---|
Henry Ji
CEO | Chief Executive Officer | 59 | 88-12-31 |
Shawn Sahebi
COO | Chief Operating Officer | - | - |
Mike A. Royal
CTO | Chief Tech/Sci/R&D Officer | 70 | 14-03-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kim D. Janda
BRD | Director/Board Member | 67 | 12-03-31 |
David Lemus
BRD | Director/Board Member | 61 | 17-09-30 |
Jaisim Shah
BRD | Director/Board Member | 63 | 13-09-10 |
1st Jan change | Capi. | |
---|---|---|
+15.55% | 118B | |
+12.66% | 106B | |
-2.53% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.92% | 15.56B | |
+6.19% | 13.63B | |
+28.83% | 12.27B |